fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis

Written by | 8 Jun 2021

Novartis,has announced the FDA has approved Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis in pediatric patients six years and older who are candidates for… read more.

Fluvoxamine for early treatment of covid-19

Written by | 8 Jun 2021

Article by Christine Clark. Evidence from trials and real world experience shows that selective serotonin reuptake inhibitors (SSRIs) are effective in treating acute covid and preventing long-haul covid.

Rejuvenating’ the Alzheimer’s brain

Written by | 8 Jun 2021

Alzheimer’s disease is the main cause of dementia and current therapeutic strategies cannot prevent, slow down or cure the pathology. The disease is characterized by memory loss, caused… read more.

Trials of fluvoxamine for covid-19

Written by | 8 Jun 2021

Interview and article by Christine Clark. Early treatment of covid-19 with fluvoxamine has been remarkably effective in two trials, one of which was funded by the Covid-19 Early… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.